Zacks: Athersys, Inc. (NASDAQ:ATHX) Given $11.00 Average Target Price by Brokerages

Athersys, Inc. (NASDAQ:ATHX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Analysts have set a one year consensus price target of $11.00 for the company and are predicting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Athersys an industry rank of 46 out of 255 based on the ratings given to related companies.

Several brokerages have commented on ATHX. Dawson James began coverage on shares of Athersys in a report on Monday, August 26th. They issued a “buy” rating and a $11.00 target price for the company. ValuEngine upgraded shares of Athersys from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

In other news, COO William Lehmann, Jr. sold 30,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $1.44, for a total value of $43,200.00. Following the completion of the sale, the chief operating officer now directly owns 542,196 shares of the company’s stock, valued at $780,762.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 15.31% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC raised its position in Athersys by 52.0% during the second quarter. Commonwealth Equity Services LLC now owns 22,795 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 7,795 shares in the last quarter. Prudential PLC raised its position in shares of Athersys by 0.3% in the second quarter. Prudential PLC now owns 4,223,097 shares of the biopharmaceutical company’s stock valued at $8,446,000 after purchasing an additional 11,200 shares during the period. NEXT Financial Group Inc raised its position in shares of Athersys by 9.3% in the third quarter. NEXT Financial Group Inc now owns 159,000 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 13,500 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Athersys in the second quarter valued at approximately $25,000. Finally, Sequoia Financial Advisors LLC raised its position in shares of Athersys by 23.1% in the second quarter. Sequoia Financial Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 15,000 shares during the period. 21.12% of the stock is currently owned by hedge funds and other institutional investors.

ATHX traded up $0.03 on Thursday, reaching $1.42. The company had a trading volume of 500,757 shares, compared to its average volume of 592,277. Athersys has a one year low of $1.20 and a one year high of $2.15. The company has a fifty day moving average of $1.34 and a 200-day moving average of $1.48. The company has a market capitalization of $217.77 million, a P/E ratio of -7.89 and a beta of 0.32.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). Athersys had a negative net margin of 458.03% and a negative return on equity of 131.22%. The company had revenue of ($0.36) million during the quarter, compared to analyst estimates of $1.51 million. Sell-side analysts forecast that Athersys will post -0.31 EPS for the current fiscal year.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Featured Article: Penny Stocks

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with's FREE daily email newsletter.